A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache (NCT05016661)
ABP-20001
This trial is No longer recruiting
Registration number NCT05016661
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Jason Ray
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR